Feb 9, 2021 | Analysis
Matrix Global Advisors (MGA) today released a new report, “Potential Savings from Accelerating US Approval of Complex Generics,” by MGA founder and CEO Alex Brill.
Sep 8, 2020 | Analysis
Matrix Global Advisors (MGA) today released a new report, “Negative Economic Impact of Restricting Drug Rebates in Medicare Part D,” by MGA founder and CEO Alex Brill. The report looks at a July 2020 Executive Order on prescription drug rebates that invokes a proposed regulatory change President Trump withdrew a year earlier.
Aug 13, 2020 | Analysis
Matrix Global Advisors (MGA) today released a new report, “The Negative Economic Effects of Medicare Buy-In and Public Option Proposals,” by MGA founder and CEO Alex Brill.
Jun 29, 2020 | Analysis
Recent data show a small decline in opioid-related mortality following a decade during which opioid-related mortality more than doubled to nearly 53,000 in 2018. However, the aggregate statistics mask important spatial and temporal trends in the data. This report estimates nationwide, regional, and county-level economic costs associated with the opioid crisis.
Jun 23, 2020 | Analysis
Last October, a new controversy erupted over the progressivity of the American tax system. The brouhaha was prompted by a new book, The Triumph of Injustice, by economists Emmanuel Saez and Gabriel Zucman. In it, the authors claim that the highest-earning Americans’ tax rate has fallen below everyone else’s.
Jun 3, 2020 | Analysis
As the United States marks the tenth anniversary of the establishment of a biosimilars pathway, many experts express frustration that the US lags behind
Europe. A new white paper from Matrix Global Advisors carefully examines the US and European biosimilars markets and finds that the comparison between the markets is nuanced.